proteínas de ligação à prostaglandina e2 usos das mesmas
The present invention encompasses prostaglandin E 2 (PGE 2 ) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E 2 and neutralize prostaglandin E 2 activity in vitro and in vivo. An...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | por |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | RONG-RONG ZHU CHUNG-MING HSIEH JIJIE GU EDIT TARCSA EILEEN BELANGER ANWAR MURTAZA CHARLES W. HUTCHINS JIANWEI SHEN MARIA C. HARRIS WILLIAM B. STINE |
| description | The present invention encompasses prostaglandin E 2 (PGE 2 ) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E 2 and neutralize prostaglandin E 2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E 2 and for inhibiting prostaglandin E 2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E 2 activity is detrimental. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BRPI0915825A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BRPI0915825A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BRPI0915825A23</originalsourceid><addsrcrecordid>eNrjZLApKMovST28Ni-xWCElVSEnMz3x8PLDi_MVDi9QAEoVlySm5yTmpWTmJSqkGimUFucDlQGV5qYW5yYW8zCwpiXmFKfyQmluBiU31xBnD93Ugvz41OKCxOTUvNSSeKegAE8DS0NTCyNTRyNjohQBAINiMtc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>proteínas de ligação à prostaglandina e2 usos das mesmas</title><source>esp@cenet</source><creator>RONG-RONG ZHU ; CHUNG-MING HSIEH ; JIJIE GU ; EDIT TARCSA ; EILEEN BELANGER ; ANWAR MURTAZA ; CHARLES W. HUTCHINS ; JIANWEI SHEN ; MARIA C. HARRIS ; WILLIAM B. STINE</creator><creatorcontrib>RONG-RONG ZHU ; CHUNG-MING HSIEH ; JIJIE GU ; EDIT TARCSA ; EILEEN BELANGER ; ANWAR MURTAZA ; CHARLES W. HUTCHINS ; JIANWEI SHEN ; MARIA C. HARRIS ; WILLIAM B. STINE</creatorcontrib><description>The present invention encompasses prostaglandin E 2 (PGE 2 ) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E 2 and neutralize prostaglandin E 2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E 2 and for inhibiting prostaglandin E 2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E 2 activity is detrimental.</description><language>por</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151103&DB=EPODOC&CC=BR&NR=PI0915825A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25544,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20151103&DB=EPODOC&CC=BR&NR=PI0915825A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RONG-RONG ZHU</creatorcontrib><creatorcontrib>CHUNG-MING HSIEH</creatorcontrib><creatorcontrib>JIJIE GU</creatorcontrib><creatorcontrib>EDIT TARCSA</creatorcontrib><creatorcontrib>EILEEN BELANGER</creatorcontrib><creatorcontrib>ANWAR MURTAZA</creatorcontrib><creatorcontrib>CHARLES W. HUTCHINS</creatorcontrib><creatorcontrib>JIANWEI SHEN</creatorcontrib><creatorcontrib>MARIA C. HARRIS</creatorcontrib><creatorcontrib>WILLIAM B. STINE</creatorcontrib><title>proteínas de ligação à prostaglandina e2 usos das mesmas</title><description>The present invention encompasses prostaglandin E 2 (PGE 2 ) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E 2 and neutralize prostaglandin E 2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E 2 and for inhibiting prostaglandin E 2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E 2 activity is detrimental.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLApKMovST28Ni-xWCElVSEnMz3x8PLDi_MVDi9QAEoVlySm5yTmpWTmJSqkGimUFucDlQGV5qYW5yYW8zCwpiXmFKfyQmluBiU31xBnD93Ugvz41OKCxOTUvNSSeKegAE8DS0NTCyNTRyNjohQBAINiMtc</recordid><startdate>20151103</startdate><enddate>20151103</enddate><creator>RONG-RONG ZHU</creator><creator>CHUNG-MING HSIEH</creator><creator>JIJIE GU</creator><creator>EDIT TARCSA</creator><creator>EILEEN BELANGER</creator><creator>ANWAR MURTAZA</creator><creator>CHARLES W. HUTCHINS</creator><creator>JIANWEI SHEN</creator><creator>MARIA C. HARRIS</creator><creator>WILLIAM B. STINE</creator><scope>EVB</scope></search><sort><creationdate>20151103</creationdate><title>proteínas de ligação à prostaglandina e2 usos das mesmas</title><author>RONG-RONG ZHU ; CHUNG-MING HSIEH ; JIJIE GU ; EDIT TARCSA ; EILEEN BELANGER ; ANWAR MURTAZA ; CHARLES W. HUTCHINS ; JIANWEI SHEN ; MARIA C. HARRIS ; WILLIAM B. STINE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BRPI0915825A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2015</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>RONG-RONG ZHU</creatorcontrib><creatorcontrib>CHUNG-MING HSIEH</creatorcontrib><creatorcontrib>JIJIE GU</creatorcontrib><creatorcontrib>EDIT TARCSA</creatorcontrib><creatorcontrib>EILEEN BELANGER</creatorcontrib><creatorcontrib>ANWAR MURTAZA</creatorcontrib><creatorcontrib>CHARLES W. HUTCHINS</creatorcontrib><creatorcontrib>JIANWEI SHEN</creatorcontrib><creatorcontrib>MARIA C. HARRIS</creatorcontrib><creatorcontrib>WILLIAM B. STINE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RONG-RONG ZHU</au><au>CHUNG-MING HSIEH</au><au>JIJIE GU</au><au>EDIT TARCSA</au><au>EILEEN BELANGER</au><au>ANWAR MURTAZA</au><au>CHARLES W. HUTCHINS</au><au>JIANWEI SHEN</au><au>MARIA C. HARRIS</au><au>WILLIAM B. STINE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>proteínas de ligação à prostaglandina e2 usos das mesmas</title><date>2015-11-03</date><risdate>2015</risdate><abstract>The present invention encompasses prostaglandin E 2 (PGE 2 ) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E 2 and neutralize prostaglandin E 2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E 2 and for inhibiting prostaglandin E 2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E 2 activity is detrimental.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | por |
| recordid | cdi_epo_espacenet_BRPI0915825A2 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | proteínas de ligação à prostaglandina e2 usos das mesmas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A11%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=RONG-RONG%20ZHU&rft.date=2015-11-03&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBRPI0915825A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |